CytoVale is a Biotech company based in San Francisco, CA. It has raised $180M in total funding. Latest round: Series D.
CytoVale funding overview
CytoVale is a Biotech company based in San Francisco, CA. CytoVale has raised $180M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series D announced in October 2024. The round record for CytoVale runs through 2024; nothing later has been disclosed. Investors on record include Sands Capital, Norwest Venture Partners, Global Health Investment Corporation (GHIC), Entree Capital, Samsung Next, Blackhorn Ventures and 2 others. 8 distinct backers are named across the disclosed rounds.
CytoVale at a glance
Total raised
$180M
Latest round
Series D
Latest round date
October 2024
Industry
Biotech
Headquarters
San Francisco, CA
Notable investors
Sands Capital, Norwest Venture Partners, Global Health Investment Corporation (GHIC), Entree Capital, Samsung Next, Blackhorn Ventures, Dol Family Ventures, Western Technology Investment
Frequently asked about CytoVale funding
How much has CytoVale raised?
CytoVale has raised $180M in total disclosed funding across the rounds on record.
Who has invested in CytoVale?
Sands Capital, Norwest Venture Partners, Global Health Investment Corporation (GHIC), Entree Capital, Samsung Next, Blackhorn Ventures are named among the investors backing CytoVale.
What was the latest CytoVale funding round?
The most recent disclosed round is a Series D, announced in October 2024.
Where is CytoVale based?
CytoVale is based in San Francisco, CA.
What sector does CytoVale operate in?
CytoVale is tracked under Biotech from San Francisco, CA, with $180M in disclosed funding.
When did CytoVale last raise?
The last disclosed CytoVale round closed in October 2024 at Series D.
CytoVale totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related Biotech companies in San Francisco below to benchmark round size and investor mix.
